MyeChild01 - International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia

  • Strong, Robyn, (Project Manager)
  • Moore, Andrew (Primary Chief Investigator (PCI))
  • Downie, Peter (Chief Investigator (CI))
  • Kotecha, Rishi S. (Chief Investigator (CI))
  • Trahair, Toby (Chief Investigator (CI))
  • Mechinaud, Francoise (Chief Investigator (CI))
  • Osborn, Michael (Chief Investigator (CI))
  • Alvaro, Frank (Chief Investigator (CI))
  • Dalla Pozza, Luciano (Chief Investigator (CI))
  • Jones, Janelle, (Project Manager)

Project: Research

Project Description

MyeChild01 is an international randomised clinical trial with the primary aim of determining which of the current treatments combined with a novel drug will provide the best chance of survival for a a child with Acute Myeloid Leukaemia (AML). Gemtuzumab ozogamicin (GO) is a promising new drug whereby a chemotherapy drug is bound to an antibody targeting the cell surface marker CD33. This marker is present in 80% of AML cases, resulting in the chemotherapy drug being delivered directly to AML cells. The study is expected to run for 5-6 years with approximately 50 Australian patients enrolled each year.
Short titleMyeChild01
AcronymMyeChild
StatusActive
Effective start/end date1/02/1831/01/23